Bruker Corporation $BRKR Stock Position Lowered by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. decreased its position in Bruker Corporation (NASDAQ:BRKR) by 17.5% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 313,409 shares of the medical research company’s stock after selling 66,687 shares during the period. Envestnet Asset Management Inc.’s holdings in Bruker were worth $12,912,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BRKR. Teacher Retirement System of Texas lifted its holdings in shares of Bruker by 5.1% in the first quarter. Teacher Retirement System of Texas now owns 29,045 shares of the medical research company’s stock valued at $1,212,000 after purchasing an additional 1,422 shares in the last quarter. OneDigital Investment Advisors LLC raised its position in Bruker by 38.0% during the first quarter. OneDigital Investment Advisors LLC now owns 5,522 shares of the medical research company’s stock valued at $230,000 after buying an additional 1,520 shares during the period. Linden Thomas Advisory Services LLC lifted its stake in Bruker by 3.5% in the 1st quarter. Linden Thomas Advisory Services LLC now owns 19,356 shares of the medical research company’s stock worth $808,000 after acquiring an additional 660 shares in the last quarter. Allworth Financial LP lifted its stake in Bruker by 92.4% in the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock worth $30,000 after acquiring an additional 364 shares in the last quarter. Finally, State of Michigan Retirement System boosted its position in Bruker by 1.1% during the 1st quarter. State of Michigan Retirement System now owns 26,493 shares of the medical research company’s stock worth $1,106,000 after acquiring an additional 300 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Price Performance

Shares of BRKR opened at $39.93 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61. The firm has a market cap of $6.06 billion, a PE ratio of 76.79, a PEG ratio of 5.31 and a beta of 1.26. The firm’s 50 day moving average price is $35.02 and its 200 day moving average price is $37.08. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $64.64.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.33 by $0.12. The company had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. Bruker’s quarterly revenue was down .5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.60 EPS. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, research analysts expect that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 2nd. Shareholders of record on Monday, December 8th will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.5%. The ex-dividend date is Monday, December 8th. Bruker’s dividend payout ratio (DPR) is -125.00%.

Insider Buying and Selling at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of the company’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the completion of the sale, the director owned 18,016 shares in the company, valued at approximately $581,016. This represents a 16.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 27.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on BRKR shares. Cowen reiterated a “hold” rating on shares of Bruker in a report on Tuesday. Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the company a “buy” rating in a research report on Monday, August 4th. Citigroup dropped their price objective on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a research note on Monday, August 4th. UBS Group increased their target price on shares of Bruker from $40.00 to $43.00 and gave the stock a “neutral” rating in a research report on Tuesday. Finally, TD Cowen lifted their target price on shares of Bruker from $40.00 to $42.00 and gave the company a “hold” rating in a research note on Tuesday. Five research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Bruker has an average rating of “Hold” and an average target price of $48.30.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.